[ Diretor: Mário Frota [ Coordenador Editorial: José Carlos Fernandes Pereira [ Fundado em 30-11-1999 [ Edição III [ Ano XII

quinta-feira, 27 de abril de 2017

Drugs firms call for phased transition of regulation after Brexit

Drugmakers hope the UK can still work closely with the EMA after Brexit through a system of reciprocal or mutual recognition.
[Ed Wohlfahrt/Flickr]
Britain currently hosts the European Medicines Agency (EMA), which acts as a one-stop-shop for approving and monitoring the safety of drugs across the bloc, but there is uncertainty about the regulatory set-up after Brexit.

With Britain facing a general election on June 8, the Association of the British Pharmaceutical Industry (ABPI) said it was important for the next government to prioritise a smooth regulatory handover.

“It is in the mutual interests of our new government and the EU to minimise the potential impact to patient health and well-being. Agreeing a phased transition for the UK’s new relationship with the EU can help prevent ‘day one’ disruption,” the trade group said in its election “manifesto”.

Drugmakers hope Britain can still work closely with the EMA after Brexit through some system of reciprocal or mutual recognition – but this idea faces significant hurdles, since Britain will be outside the EU single market.

Sem comentários: